RxDoctor Payments DataLook up a doctor →

Sarang Mangalmurti, MD

Cardiovascular Disease · Bryn Mawr, PANPI 1790984003

Payments from drug & device makers

$1,312,565in general payments, 2019–2025

Across 1,022 payments — averaging $1284.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$833K
  • Philips North America LLC$201K
  • Contego Medical, Inc$81K
  • Cardiovascular Systems Inc.$52K
  • Cagent Vascular Inc$49K
  • Abbott$43K
  • plus $54K from 47 others
$10,000in research payments, 2019–2025

Across 1 payment — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vesalio, Inc.$10K

What the payments were for

  • Consulting fees$358,51349%
  • Speaking & faculty fees$273,73838%
  • Travel & lodging$24,5723%
  • Food & beverage$36,8205%
  • Education$34,0115%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,312,565 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$637,165
Medicare patients
1,024
Services billed
3,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$101,669
XareltoRivaroxaban54$53,884
Repatha SureclickEvolocumab24$22,391
EntrestoSacubitril/Valsartan20$20,081
BrilintaTicagrelor18$16,799
ClopidogrelClopidogrel Bisulfate216$3,869
Metoprolol Succinate142$2,540
Atorvastatin Calcium159$2,112
Rosuvastatin Calcium55$1,175
Losartan Potassium44$983
Nitroglycerin17$961
Isosorbide Mononitrate ErIsosorbide Mononitrate23$859
Diltiazem 24hr Er (Cd)Diltiazem Hcl17$646
Amlodipine Besylate72$583
Ezetimibe31$542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$780$101,66991 claims
Johnson & JohnsonXarelto$555$53,88454 claims
NovartisEntresto$555$20,08120 claims
AstraZenecaBrilinta$29,023$16,79918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Bryn Mawr

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →